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tients from both cooperative groups and 10 feasibility
problems occurred in the multicenter setting. Patients re-
ported mixed patterns of responses regarding the different
domains of QoL. Treatment-related effects could be ob-
served. In general, severe limitations in perceived QoL dur-
ing the first 3 years of follow-up were reported. In particu-
lar, levels of emotional strain and fatigue remained high
after the end of active treatment. Women in general re-
ported a lower QoL than men.
CONCLUSION: QoL assessment within international
multicenter trials in HD proved feasible within the two dif-
ferently organized study groups of EORTC and GHSG.
The applied H8/HD8 QoL questionnaire was able to de-
tect distinct patterns of QoL in subgroups of patients.
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OBJECTIVES: Gemcitabine is a new anticancer drug that
has recently been proposed for the treatment of advanced
pancreatic cancer. The therapy with gemcitabine has been
reported to confer a survival advantage in comparison
with fluorouracil. Because gemcitabine is expensive, we
estimated the cost per life-year gained using gemcitabine
for this clinical indication.
METHODS: The clinical material utilized in our analysis
was derived from a randomized clinical trial in which the
survival of patients receiving gemcitabine was compared
with that of patients receiving fluorouracil. To obtain an
estimate of effectiveness, the survival curves published in
the trial were analyzed using the Gompertz methodology.
Gemcitabine acquisition cost was based on wholesale
price in Italy, in the UK and in the US. The overall cost of
treatment is presently being estimated by collecting indi-
vidual data on the use of resources and morbidity costs.
RESULTS: The analysis of the survival curves showed
that the mean survival of patients treated with gemcitab-
ine was 6.29 months, while the corresponding value for
patients receiving standard treatment was 3.20 months
(both values include discounting at an annual rate of
3%). The survival gain for the gemcitabine group was 2.9
months per patient. Our analysis of cost data for these
two treatments is in progress, but preliminary data show
that the incremental cost is less than $20,000 per patient. 
CONCLUSIONS: In pancreatic cancer, gemcitabine de-
termines a survival gain of approximately 3 months. Its
cost-effectiveness profile seems to be within acceptable
values.
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OBJECTIVE: To collect resource utilization and unit costs
in Belgium for treatment of severe neutropenia of five
chemotreated cancer types for which no reimbursement of
prophylactic Neupogen use is available. These cancer types
include multiple myeloma (MM), metastatic breast cancer,
small cell lung cancer, non–small cell lung cancer, and blad-
der cancer. Another goal is to identify factors that may ex-
plain cost variation in treatment of severe neutropenia.
METHODS: Retrospective data collection of bills from
patients treated for severe neutropenia from nine hospital
centers spread all over Belgium over a period of 1 year
(1/96–1/97). Severe neutropenia was defined as a neutro-
penic episode requiring hospitalization. Only direct medi-
cal costs were considered from the perspective of reim-
bursement. Items collected included: hospital stay (duration
and type), diagnostic procedures, drugs, transfusions, in-
terventions; and medical consults.
RESULTS: Seventy-nine patient bills were collected. More
than 75% of the registered neutropenic events occurred dur-
ing first three chemo cycles. Total mean cost (35 Bfr  1
US$) was $4.918 (Med.: $4.529; 95% CI: $4.303–$5.533).
DISCUSSION: Multiple regression analysis demonstrates
that two factors (hospital duration and institution type)
explain 85% of the cost variation. The institution factor
may, however, mask a bias, as all the hematological can-
cers (17%) with their more costly treatment procedures
for neutropenia were treated in university centers. 85%
of treatment cost is composed of only three factors: hos-
pital stay (60%); drug regimen (15%); and lab tests per-
formed (10%). 
CONCLUSION: The treatment cost of neutropenia var-
ies. Its spread is skewed to the right. It is appropriate to
calculate geometric mean cost and to introduce specific
cost estimates per institution type or per cancer type (he-
matological/nonhematological).
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Febrile neutropenia (FN) represents one of the leading
dose-limiting toxicities of cancer chemotherapy. CSFs have
been shown to reduce the incidence of FN in a variety of
settings. Cost-minimization models have established FN
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risk thresholds (FNRTs) for primary prophylaxis with
CSFs.
OBJECTIVES: To determine the impact of CPMs on
FNRT estimates with the CSFs.
METHODS: Cost-minimization models based on stan-
dard decision theory were generated, incorporating 1)
probabilities and resource utilization from randomized
clinical trials and 2) unit cost information from local in-
stitutional sources. Sensitivity analyses were performed,
varying resource use, costs, and test performance charac-
teristics. FNRTs were derived at which cost equivalence
was reached in each model. The test performance of pos-
sible CPMs was assessed utilizing the likelihood ratio
(LR) for discriminating high-risk patients with probabil-
ity (prob[HR]).
RESULTS: Baseline cost-minimization models were
equated with CPMs with a LR  1.0. The FNRT for CSF
use decreases as hospitalization length of stay (LOS) or
cost/day increase. Any CPM associated with a LR
1
generates lower FNRTs than under baseline conditions.
Test efficiency of the CPMs improves with increasing
LR
, with optimal performance observed between 2.0
and 4.0. In balanced CPMs with LR
  3.0, FNRTs are
reached for costs/day of $1000, $1500, and $2000 at
0.21, 0.16, and 0.13 respectively. In unbalanced CPMs,
FNRTs are 10% at prob(HR)  0.4, 0.3, 0.2, and 0.1
at costs/day of $1700, $1000, $600, and $300, respec-
tively. 
CONCLUSIONS: Efficient CPMs to identify high-risk pa-
tients should be able to further reduce costs and FNRTs
for CSF use based on cost-minimization.
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OBJECTIVE: To evaluate the QoL of Ig-NHL patients
enrolled in a trial comparing the efficacy and safety of F
and CVP.
METHODS: The EORTC-QLQ-C30 (v1) questionnaire
was completed by all French- and English-literate patients
at baseline, during treatment, and after treatment. QoL
was expressed as a global health status (QL) and five
functional scores (FS); physical, emotional, social (SF), cog-
nitive (CF) and role (RF), for which high values indicate
better QoL. It was also expressed as eight symptom/single
item (SSI) scores: fatigue, nausea, and vomiting (NV),
pain, dyspnea (DY), insomnia, appetite loss, constipation
(CO), diarrhea (DI), and financial difficulties (FI) for
which lower values mean better QoL.
RESULTS: Of the 91 patients recruited (F  47, CVP 
44), 84 completed the questionnaire at baseline, 74 dur-
ing treatment, and 41 after treatment. All FS were high at
baseline (70–90) and varied from 1 to 12 points during
the study. All FS improved during treatment except CF
and QL in the F group, which remained unchanged; and
RF and SF in the CVP group, which deteriorated. The dif-
ference between groups reached statistical significance for
SF (p  0.0076) but not for RF (p  0.4597). All SSI
scores were low (10 to 40) and varied only slightly during
the trial. Most scores improved except DY and CO in the
F group and NV, CO, DI, and FI in the CVP group. 
CONCLUSIONS: QoL was high in these patients. The
higher incidence of nausea, vomiting, and alopecia ob-
served in the CVP group may explain the difference ob-
served for SF, and, to a lesser extent, RF.
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OBJECTIVE: The objective of this study was to deter-
mine the relationship between profile-based cancer-spe-
cific quality of life dimension scores, and EuroQol-5D
scores in a breast cancer surgery sample.
METHODS: Seventy-five breast cancer surgery patients
participated in the study. The patients completed the Func-
tional Living Index-Cancer (FLIC), the Functional Assess-
ment of Cancer Therapy-General Version (FACT-G), and
the EuroQol-5D (EQ-5D) at the same visit, and the order
of instruments was randomized. Scores on both the EQ-5D
classification system, as well as on the thermometer, were
obtained, and both scores were related to dimension scores
on the FLIC and the FACT-G. Information on the age of
the patient, the cancer stage, and the number of comorbid-
ities was obtained through chart review.
RESULTS: The mean age of patients was 60 (SD  10.7).
The majority of patients (96%) were diagnosed with ei-
ther stage I or stage II breast cancer. Over 90% of pa-
tients had up to three comorbid conditions, with hyperten-
sion being the most frequent. Mean scores on the EQ-5D
classification system and the thermometer were 87.4
(SD  13.6), and 86.6 (SD  12.6), respectively. Ceiling
effects were observed on the classification system as well
as the thermometer. Both linear and double log regres-
sion results showed that quality of life dimension scores
were significantly related to scores in both the EQ-5D
classification systems and the thermometer. FLIC dimen-
sion scores made statistically significant contributions to
the EQ-5D classification score, but not to the score ob-
tained on the thermometer. FACT-G dimension scores
did not contribute significantly to either the EQ-5D clas-
sification score or to the thermometer score.
CONCLUSION: The results of this study show that can-
